Merck & Co., Inc. (MRK)

83.15
NYSE
Prev Close 82.63
Day Low/High 81.85 / 83.48
52 Wk Low/High 65.25 / 92.64
Exchange NYSE
Shares Outstanding 2529.24B
Market Cap 208.99B
P/E Ratio 20.01
Div & Yield N.A. (N.A)
Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

In a "take no pain, take no prisoners" market, health care stocks languish.

Cramer: Here's the Secret to Driving Stocks Higher in This Market

Cramer: Here's the Secret to Driving Stocks Higher in This Market

Posting results 'not as a bad as we thought' has become a successful strategy. It worked for Bristol.

Scynexis: Small Biopharma, Big Potential

Scynexis: Small Biopharma, Big Potential

This small-cap firm has a lot going for it.

Intermediate Trade: Bristol-Myers

Intermediate Trade: Bristol-Myers

The pharmaceutical giant has reason to be optimistic about its earnings release tomorrow.

Scanning the Earnings Universe, Plus Overnight Tidbits

Thus far I am seeing a mixed picture of earnings reports this morning and last night. Visa guided a bit lower on a more costly Visa Europe integration, Whirlpool misses and cuts guidance, and Lilly results were well below on both earnings per share ...

Markets Await Apple Earnings on Tuesday

Markets Await Apple Earnings on Tuesday

On Tuesday, October 25, Apple reports fiscal fourth quarter results after the markets close.

Technical Picture Remains Mixed

Since mid- July there have been numerous negative divergences. One clear example is the chart below of new highs. During this three-and-a-half month period the S&P 500 has traded in a range above 2125 (the post-Brexit breakout). Downside attempts li...

It's Not Easy Being Green: 3 Solid Names That Stand Out

It's Not Easy Being Green: 3 Solid Names That Stand Out

Look for solid companies showing life.

Merck upgraded at Merrill

Merck's Breakout Is Just Getting Started

Merck's Breakout Is Just Getting Started

The stock's healthy recent pattern appears to be giving way to a fresh bull leg.

Trending Tickers: MRK, BMY, TSRO, TWLO, CRM

Trending Tickers: MRK, BMY, TSRO, TWLO, CRM

Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.

Midday Report: Stocks Fueled by Oil Gains; Mylan Settles With U.S. Government

Midday Report: Stocks Fueled by Oil Gains; Mylan Settles With U.S. Government

U.S. stocks rose Monday as Wall Street looked past Sunday night's bitter presidential debate, focusing instead on oil's 3% rally and the looming start of earnings season.

Nervous Pooch? There's a Drug for That

Nervous Pooch? There's a Drug for That

Zoetis is not averse to a little noise as investors, analysts take notice.

Merck to Discontinue Osteoporosis Drug Development

Merck to Discontinue Osteoporosis Drug Development

Merck has decided to discontinue the development of its osteoporosis drug and will not seek regulatory approval for its use.

Intermediate Trade: Merck

Intermediate Trade: Merck

The tactic is a slightly out-of-the-money, bearishly biased vertical put spread expiring in November.

Cramer: The 'Just You Wait' Crowd Keeps Waiting

Cramer: The 'Just You Wait' Crowd Keeps Waiting

The market continues to defy those players who believe we are seeing the calm before the storm.

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

It's Time to Go Short Stocks; Here Are Some Ideas

It's Time to Go Short Stocks; Here Are Some Ideas

Besides Tesla, Twitter and Biogen make good candidates.

4 Stocks to Avoid Amid the Mad 'Search for Yield'

4 Stocks to Avoid Amid the Mad 'Search for Yield'

There's a price to pay for low expectations.

Don't Write Off Bristol-Myers After Opdivo Setback

Don't Write Off Bristol-Myers After Opdivo Setback

BMY is unlikely to stay in the low $60s for long.

The Ironic Chess Game of Bristol-Myers

The Ironic Chess Game of Bristol-Myers

The failed trial is among the biggest single blows by a major pharma player.

Trending Tickers: CHK, MUR, MRO, BMY

Trending Tickers: CHK, MUR, MRO, BMY

Rising crude prices help buoy a host of oil companies Monday.

Bristol-Myers Downgraded, Credit Suisse Lowers Price Target

Bristol-Myers Downgraded, Credit Suisse Lowers Price Target

Credit Suisse downgraded Bristol-Myers Squibb to NEUTRAL from OUTPERFORM and lowered its price target to $63 from $86 following the latest announcement on Opdivo.

Merck Gets a Big Shot in the Arm

Merck Gets a Big Shot in the Arm

One day does not make a trend, but one day can certainly reinforce an existing trend.

Morning Movers: MFRM, DAL, AMZN, BMY

Morning Movers: MFRM, DAL, AMZN, BMY

Mattress Firm soars on takeover bid, while Delta's worldwide computer issues are causing the stock to drop.

Merck upgraded at Credit Suisse

What Next for Bristol-Myers and Merck?

What Next for Bristol-Myers and Merck?

BMY's loss definitely looks like MRK's gain.

My Takeaways and Observations

Peak Trump. The conditions I anticipated in my previous day's column (Trump's fall) -- a widening in the poll differentials between Trump and Clinton --- is already occurring.  Tesla TSLA, Part Deux.  The market was up at the get go, but we saw a ve...

Trending Tickers: BMY, MRK, FEYE, WING

Trending Tickers: BMY, MRK, FEYE, WING

Bristol-Myers Squibb fell sharply after its lung cancer treatment failed a clinical trial.

Gilead and Teva: Off-the-Charts Cheap

Gilead and Teva: Off-the-Charts Cheap

Rarely do investors get to buy these types of quality businesses at such discounted prices.